BRPI0907494A2 - ácido rubonucleicos de pequena interferência (sirna) catiônicos, composições farmacêuticas, aplicação de ácidos rubonucleicos de pequena interferência (sirna) catiônicos e processo de síntese automatizado de um filamento de ácido rubonucleico de pequena interferência (sirna) catiônico. - Google Patents

ácido rubonucleicos de pequena interferência (sirna) catiônicos, composições farmacêuticas, aplicação de ácidos rubonucleicos de pequena interferência (sirna) catiônicos e processo de síntese automatizado de um filamento de ácido rubonucleico de pequena interferência (sirna) catiônico.

Info

Publication number
BRPI0907494A2
BRPI0907494A2 BRPI0907494A BRPI0907494A BRPI0907494A2 BR PI0907494 A2 BRPI0907494 A2 BR PI0907494A2 BR PI0907494 A BRPI0907494 A BR PI0907494A BR PI0907494 A BRPI0907494 A BR PI0907494A BR PI0907494 A2 BRPI0907494 A2 BR PI0907494A2
Authority
BR
Brazil
Prior art keywords
acid
rubonucleic
sirna
cationic
filament
Prior art date
Application number
BRPI0907494A
Other languages
English (en)
Portuguese (pt)
Inventor
Behr Jean-Paul
Remy Jean-Serge
Kotera Mitsuharu
Pfender Nadége
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of BRPI0907494A2 publication Critical patent/BRPI0907494A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0907494A 2008-01-30 2009-01-30 ácido rubonucleicos de pequena interferência (sirna) catiônicos, composições farmacêuticas, aplicação de ácidos rubonucleicos de pequena interferência (sirna) catiônicos e processo de síntese automatizado de um filamento de ácido rubonucleico de pequena interferência (sirna) catiônico. BRPI0907494A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0800492A FR2926818B1 (fr) 2008-01-30 2008-01-30 siRNA CATIONIQUES, SYNTHESE ET UTILISATION POUR L'ARN INTERFERENCE
PCT/IB2009/050379 WO2009095887A1 (fr) 2008-01-30 2009-01-30 siRNA CATIONIQUES, SYNTHÈSE ET UTILISATION POUR L'ARN INTERFÉRENCE

Publications (1)

Publication Number Publication Date
BRPI0907494A2 true BRPI0907494A2 (pt) 2019-09-24

Family

ID=39683957

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907494A BRPI0907494A2 (pt) 2008-01-30 2009-01-30 ácido rubonucleicos de pequena interferência (sirna) catiônicos, composições farmacêuticas, aplicação de ácidos rubonucleicos de pequena interferência (sirna) catiônicos e processo de síntese automatizado de um filamento de ácido rubonucleico de pequena interferência (sirna) catiônico.

Country Status (13)

Country Link
US (1) US10927371B2 (enExample)
EP (1) EP2250267B1 (enExample)
JP (1) JP2011511776A (enExample)
KR (1) KR20100120293A (enExample)
CN (1) CN101960009A (enExample)
AU (1) AU2009208646A1 (enExample)
BR (1) BRPI0907494A2 (enExample)
CA (1) CA2713075A1 (enExample)
FR (1) FR2926818B1 (enExample)
IL (1) IL207290A0 (enExample)
NZ (1) NZ587117A (enExample)
RU (1) RU2010136047A (enExample)
WO (1) WO2009095887A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006325054B2 (en) * 2005-12-15 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
WO2015015498A1 (en) * 2013-07-31 2015-02-05 Qbi Enterprises Ltd. Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
AU2016226418B2 (en) 2015-03-02 2022-05-26 Synthetic Genomics, Inc. Regulatory elements from labyrinthulomycetes microorganisms
US10633454B2 (en) 2016-11-01 2020-04-28 Conagen Inc. Expression of modified glycoproteins and glycopeptides
EP3535385A4 (en) * 2016-11-01 2020-06-17 Conagen Inc. EXPRESSION OF MODIFIED GLYCOPROTEINS AND GLYCOPEPTIDES
CN106498072B (zh) * 2016-11-24 2019-09-10 青岛千卓分子生物科技有限公司 一种液态产品中外源dna内标物的保护方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071890A (en) 1994-12-09 2000-06-06 Genzyme Corporation Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
DE10207177A1 (de) 2002-02-19 2003-09-04 Novosom Ag Fakultativ kationische Lipide
US20040019008A1 (en) 2002-05-28 2004-01-29 Lewis David L. Compositions and processes using siRNA, amphipathic compounds and polycations
JP2004137143A (ja) 2002-08-21 2004-05-13 Fuji Photo Film Co Ltd 有機変性層状珪酸塩及びその組成物
EP1585756B1 (en) * 2002-11-26 2010-04-21 University of Massachusetts Delivery of sirnas
EP1638919B1 (en) * 2003-06-18 2012-09-26 Biolab Ltd. Sphingolipids polyalkylamines conjugates
WO2005060697A2 (en) * 2003-12-19 2005-07-07 Chiron Corporation Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
US20060073505A1 (en) * 2004-09-21 2006-04-06 Isis Pharmaceuticals, Inc. Oligomeric compounds effecting drosha-mediated cleavage
JP2008519053A (ja) * 2004-11-04 2008-06-05 アンディーノ，ラウル 小さい干渉ＲＮＡ（ｓｉＲＮＡ）のポリアミン共役体の合成及びそれによって形成された共役体
CA2587962A1 (en) * 2004-11-17 2006-06-08 University Of Maryland, Baltimore Highly branched hk peptides as effective carriers of sirna
AU2006325054B2 (en) 2005-12-15 2013-05-02 Centre National De La Recherche Scientifique (Cnrs) Cationic oligonucleotides, automated methods for preparing same and their uses
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2992875A1 (en) * 2006-04-20 2016-03-09 Silence Therapeutics GmbH Lipoplex formulations for specific delivery to vascular endothelium

Also Published As

Publication number Publication date
AU2009208646A1 (en) 2009-08-06
JP2011511776A (ja) 2011-04-14
US10927371B2 (en) 2021-02-23
CA2713075A1 (fr) 2009-08-06
EP2250267B1 (fr) 2016-09-14
CN101960009A (zh) 2011-01-26
EP2250267A1 (fr) 2010-11-17
FR2926818B1 (fr) 2012-04-06
KR20100120293A (ko) 2010-11-15
WO2009095887A1 (fr) 2009-08-06
IL207290A0 (en) 2010-12-30
FR2926818A1 (fr) 2009-07-31
NZ587117A (en) 2012-09-28
RU2010136047A (ru) 2012-03-10
US20110118331A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
PT2121578T (pt) Processo de preparação de ácido 5-bifenil-4-amino-2-metil-pentanoico
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
BRPI0718339A2 (pt) Composto, composição, composição farmacêutica e processo de fabricação de tanato de rasagilina
BRPI0923795A2 (pt) composição detergente aquosa estruturada e processo de produção da mesma
BRPI0720068A2 (pt) Processo para preparar nanocápsulas, produto, nanocápsulas e composição
BRPI0818533A2 (pt) composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI1013929A2 (pt) processo de fabricação de um substrato fibroso, substrato fibroso, e, utilização de um substrato fibroso
BRPI0907223A2 (pt) Processo para fabricação de produtos estampados, e produtos estampados preparados a partir do mesmo
BRPI0910689A2 (pt) processo de síntese de rna por via química
BRPI0906249A2 (pt) Processo de elaboração de 1,1,1,4,4,4-hexafluoro-2-buteno
BRPI1011888A2 (pt) processo para preparar um composto, e, composição.
BRPI1014547A2 (pt) composto, e, processo para preparar um composto.
BRPI0821801A2 (pt) Zeólito e processo de preparação de um zeólito.
BRPI1005940A2 (pt) processo para preparar compostos de 2-nitrobifenila de fórmula i, compostos de 2-aminobifenila de fórmula vi, n-acil-2-aminobifenilas da fórmula geral (vii), composto de fórmula i, composto de fórmula ii, composto de fórmula iii e composto de fórmula x.1 ou x.2
BRPI0806957A2 (pt) Processo para produzir um ácido polilático, ácido polilático, e, artigo moldado.
BRPI1014691A2 (pt) Composto, e, processo para a preparação de um composto.
BRPI1014436A2 (pt) composto, processo de preparação de um composto, intermediário, composições farmacêuticas, e, utilização de um composto.
BRPI0919642A2 (pt) composição para cuidados domésticos, utilização de um nanogel catiônico e processo de realização de cuidados domésticos.
BRPI0921882A2 (pt) processo para fabricar um composto.
BRPI1011130A2 (pt) composto organometálico, processo de preparação de um composto organometálico,e, utilização de um composto organometálico.
BR112012004652A2 (pt) composições de soluções concentradas compreendendo metal do grupo vi, metal do grupo viii e fósforo e processo de formação
BRPI0907494A2 (pt) ácido rubonucleicos de pequena interferência (sirna) catiônicos, composições farmacêuticas, aplicação de ácidos rubonucleicos de pequena interferência (sirna) catiônicos e processo de síntese automatizado de um filamento de ácido rubonucleico de pequena interferência (sirna) catiônico.
BRPI1007654A2 (pt) composto, processo para a obtenção de um composto de fórmula geral e composição farmacêutica
BRPI0817721A2 (pt) Composto, composição farmacêutica, método de tratamento, e, processo para preparação de um composto
BRPI1011803A2 (pt) novo processo.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

Owner name: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) ; UNIVERSITE DE STRASBOURG (FR)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.